The 2024 European guideline on the management of epididymo-orchitis
Abstract
The European guideline on the management of epididymo-orchitis has been updated in 2024. This guideline offers advice on the diagnosis, investigation, treatment and follow-up for the management of epididymo-orchitis. For treatment of patients with a history suggestive of sexually transmitted pathogens-ceftriaxone dose increased to 1 g intramuscularly (IM) single dose alongside doxycycline. The use of dual therapy with azithromycin is no longer recommended, unless cefixime is being given as an alternative to ceftriaxone. For treatment of patients with a history including risks for both sexually transmitted and enteric pathogens-ceftriaxone IM single dose and either ofloxacin or levofloxacin is recommended. Where enteric pathogens are suspected as the likely cause, either ofloxacin or levofloxacin is recommended as monotherapy. This guideline covers a range of clinical scenarios, including rarer and non-sexually transmitted causative agents.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.